Pancreatic ductal adenocarcinoma (PDAC) is recognized as one of the most aggressive malignancies, with a dismal 5-year survival rate nearing 13% [1]. Early lymph node metastasis (LNM), along with aggressive tumor growth, represents a defining biological characteristic of PDAC and serves as a strong independent predictor of poor clinical outcomes [2]. Notably, N0 patients exhibit a significantly higher 5-year survival rate compared to N1/2 patients (57.1% vs. 25.0%) [3]. Neoadjuvant therapy is re…